What happens next in GLP-1 — and when.

Get the briefing

What moved in the GLP‑1 field, in your inbox.

@glp1briefing

IndicationsCardiovascular disease › semaglutide

semaglutide in cardiovascular disease

semaglutide is approved in the US for cardiovascular disease, and has 22 trials on file here in this condition. 19 of them are phase 3 or later. The next scheduled result is 2026-12-31.

22 registered trials study semaglutide (Rybelsus, Wegovy, Ozempic) in cardiovascular disease, 16 of them still active and 9 in phase 3. The next is due to report 2026-12-31.

Trials on file
22
Active
16
Active phase 3
9
Participants in active trials
20,217
Sponsors
21
Scheduled readouts
7

Scheduled to report

Dates are filed by the sponsor and move often. Each links to its own record and change history.

Est. completionTrialPhaseParticipants
2026-12-31Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study)
NCT06959784 · China-Japan Friendship Hospital
P4142
2027-01Epicardial Cardiac Fat-CT (EPIC-CT)
NCT07297589 · Instituto Mexicano del Seguro Social
P3136
2027-04DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies
NCT07483801 · Cambridge University Hospitals NHS Foundation Trust
P4112
2027-07-31Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial
NCT07030621 · RenJi Hospital
P3436
2027-09-01REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels
NCT05669755 · Novo Nordisk A/S
P37,101
2028-02Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment
NCT06788626 · Wei Hu
P3390
2029-01-01Screening and Intervention for Subclinical Coronary Artery Disease in Patients With Type 2 Diabetes
NCT05700877 · Per Løgstrup Poulsen
P47,300

All trials on file

Every registered trial of semaglutide grouped under cardiovascular disease, largest first. Grouping follows the registry’s own condition wording.

TrialStatusPhaseSponsor
Screening and Intervention for Subclinical Coronary Artery Disease in Patients With Type 2 DiabetesRecruitingP4Per Løgstrup Poulsen
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood VesselsActive, not recruitingP3Novo Nordisk A/S
Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes
NCT06082063
RecruitingP3Steno Diabetes Center Copenhagen
Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy
NCT07511543
Not yet recruitingP3Population Health Research Institute
Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome
NCT07770282
Not yet recruitingP3All India Institute of Medical Sciences, Bhubaneswar
Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled TrialNot yet recruitingP3RenJi Hospital
Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular TreatmentNot yet recruitingP3Wei Hu
Acute Subcutaneous SemaglutidE in Acute Ischemic sTroke
NCT05630586
RecruitingP2Aarhus University Hospital
Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetes
NCT07254572
RecruitingP4National Institute of Cardiology, Warsaw, Poland
Focusing on the Menopausal Transition to Improve Mid-Life Women's Health
NCT06975111
RecruitingP2/P3University of Colorado, Denver
GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV
NCT07221214
RecruitingP2Vanderbilt University Medical Center
Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study)Enrolling by invitationP4China-Japan Friendship Hospital
The POST-ACS Study
NCT05322200
UnknownP4Swansea Bay University Health Board
Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion Therapies
NCT05920889
CompletedP2Chinese University of Hong Kong
Semaglutide Treatment On Coronary Progression
NCT03985384
CompletedP4Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Epicardial Cardiac Fat-CT (EPIC-CT)RecruitingP3Instituto Mexicano del Seguro Social
Effect Of Semaglutide In Coronary Atheroma Plaque
NCT05071417
UnknownP3Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot StudiesNot yet recruitingP4Cambridge University Hospitals NHS Foundation Trust
Semaglutide and Vascular Regeneration
NCT05870462
UnknownP4Canadian Medical and Surgical Knowledge Translation Research Group
Effect of Oral Semaglutide on Epicardial and Pericoronary Adipose Tissues in Type 2 Diabetes After Myocardial InfarctionUnknownP4University of Sao Paulo General Hospital
Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes
NCT05780905
RecruitingP4University of Washington
Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)
NCT07295223
RecruitingP3Instituto Mexicano del Seguro Social

See the full record for semaglutide, or every molecule being studied in cardiovascular disease. These are registered trials, nothing more. Most drugs tested in a new condition never get approved for it, and plenty of these will report nothing useful.